نتایج جستجو برای: accelerated rush immunotherapy

تعداد نتایج: 97423  

2012
Angelika Sager Margitta Worm

Abstracts of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, Méxicos of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, México ORAL ABSTRACT SESSION ALLERGEN IMMUNOTHERAPY 1 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens Michaela Gruber, a...

2012
María Isabel Rojo Gutiérrez Misael Gonzalez-Ibarra Teresa Sandoval Jaime Mellado-Abrego

Abstracts of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, Méxicos of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, México ORAL ABSTRACT SESSION ALLERGEN IMMUNOTHERAPY 1 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens Michaela Gruber, a...

2015
Masaya Takahashi Shoichiro Taniuchi Kazuhiko Soejima Yasuko Hatano Sohsaku Yamanouchi Kazunari Kaneko

BACKGROUND Rush oral immunotherapy (OIT) combined with omalizumab (OMB) has been reported to be an effective and safe treatment for severe milk allergies. However, no report has described long-term follow-up observations after OMB discontinuation. The purpose of this case report was to evaluate the safety and efficacy of rush OIT in combination with OMB during a long period of treatment. CASE...

2012
Michaela Gruber Ulrich Amon

Abstracts of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, Méxicos of the XXII World Allergy Congress, 4–8 December, 2012 Cancún, México ORAL ABSTRACT SESSION ALLERGEN IMMUNOTHERAPY 1 1 Ultra-Rush Specific Immune Therapy with Depigmented and Polymerized Allergen Extracts is Effective and Safe in Patients With Severe SAR Highly Sensitized against Pollen Allergens Michaela Gruber, a...

Journal: :Journal of investigational allergology & clinical immunology 2006
A B Dursun B A Sin F Oner Z Misirligil

Allergen immunotherapy (IT) has encouraging therapeutic outcomes but its safety is still being questioned because of possible severe systemic reactions. The aim of this study was to determine the frequency of systemic reactions (SR), and to identify their correlation with the characteristics of therapy, such as allergen composition and IT schedule, and diagnosis. We analyzed the data of 126 pat...

2014
Philippe Bégin Tina Dominguez Shruti P Wilson Liane Bacal Anjuli Mehrotra Bethany Kausch Anthony Trela Morvarid Tavassoli Elisabeth Hoyte Gerri O’Riordan Alanna Blakemore Scott Seki Robert G Hamilton Kari C Nadeau

BACKGROUND Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein. OBJECTIVE To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protoco...

Journal: :Annals of agricultural and environmental medicine : AAEM 2014
Ewa Cichocka-Jarosz Marek Sanak Andrzej Szczeklik Piotr Brzyski Jacek J Pietrzyk

INTRODUCTION AND OBJECTIVE Mast cells (MC) are effector cells during severe systemic reactions (SR) to Hymenoptera stings. Venom specific immunotherapy (VIT) is the treatment of choice for prevention of SR to stings. Tryptase and prostaglandin D₂ metabolites (PGD₂) are the markers of MC activation. The study design was to 1. compare baseline values of serum tryptase concentration (BST) and PGD₂...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید